Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Försök med adaptiv dengue antiviral plattform (ADAPT)

23 september 2026 uppdaterad av: Oxford University Clinical Research Unit, Vietnam

Adaptive Dengue Antiviral Platform Trial (ADAPT): en fas 2 randomiserad, adaptiv, öppen etikettstudie för antiviral screening hos patienter med tidig symtomatisk dengue

This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection

  • Primary objectives:

    • To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection
    • To assess the safety and tolerability of the experimental drug(s) in dengue patients
  • Secondary objective:

    • To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters

Studieöversikt

Detaljerad beskrivning

This is a randomized, open-label adaptive platform trial investigating the antiviral effectiveness of various intervention arms in patients with lab-confirmed dengue and less than 48 hours of fever. The antiviral candidates in this trial will include the repurposed antiviral drugs, novel small molecule drugs and dengue monoclonal antibody. Patients will be randomly allocated between available treatment arms and compared to standard of care ("no study drug": no placebos will be made for this trial).

The current sites include Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam and Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia. Local ethical approvals have been released. Other sites and countries may be added in due course.

This is a continually running adaptive platform trial, which begins with initial candidate drugs (a total of 4 arms): molnupiravir, remdesivir and VIS513 (a dengue monoclonal antibody). New therapies may be added and poorly performing arms or interventions meeting pre-specific thresholds for in vivo antiviral efficacy will be removed.

The sample size is adaptive with multiple planned interim analyses. The number of patients recruited depends on the results. For each intervention studied the sample size will be adaptive and determined by pre-specified stopping rules for futility and efficacy. Patients are invited to participate in the trial if they present at the healthcare settings with early symptomatic dengue virus infection (less than 48 hours since the onset of fever and positive NS1 antigen test) and can be able to return for follow up visits at 30 and 60 days after randomization.

The randomization ratios will be uniform for all available and eligible arms (1:1:1...).

Studietyp

Interventionell

Inskrivning (Beräknad)

500

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Sophie Yacoub, MD., PhD.
  • Telefonnummer: +84 77728736
  • E-post: syacoub@oucru.org

Studera Kontakt Backup

  • Namn: Clinical Trials Unit Oxford University Clinical Research Unit
  • Telefonnummer: +84 28 3924 1983
  • E-post: CTU-Ethics@oucru.org

Studieorter

      • Kuala Lumpur, Malaysia, 59100
        • Har inte rekryterat ännu
        • Universiti Malaya Medical Centre
        • Kontakt:
          • Hang Cheng Ong, Doctor
      • Ho Chi Minh City, Vietnam, 700000
        • Rekrytering
        • Hospital for Tropical Diseases, Ho Chi Minh city
        • Kontakt:
          • Lan TH Nguyen, Doctor
        • Huvudutredare:
          • Lan TH Nguyen, Doctor
        • Underutredare:
          • Trieu T Huynh, Doctor
        • Underutredare:
          • Tho V Phan, Doctor
        • Underutredare:
          • Huy X Vo, Doctor
        • Underutredare:
          • Huong TC Nguyen, Doctor
        • Underutredare:
          • Phong T Nguyen, Doctor
        • Underutredare:
          • Vien TD Tran, Doctor
        • Underutredare:
          • Men TH Pham, Doctor
        • Underutredare:
          • Quy T Vo, Doctor

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

10 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Female or male patients with a clinical diagnosis of dengue virus infection and less than 48 hours of fever
  • Positive NS1 rapid diagnostic test
  • >= 10 years or ≥ 18 years of age (depending on license of therapeutic being evaluated)
  • Patient is able to give written informed consent or assent for full participation in the study.
  • Agreement to stay in hospital for duration of the intervention (most will be 5 days) and follow-up visits at day 30 and 60 post enrolment.

Exclusion Criteria:

  • Meets criteria for severe dengue at baseline (severe plasma leakage leading to dengue shock syndrome, fluid accumulation with respiratory distress, severe bleeding, severe organ involvement - AST/ALT>1000 U/L, impaired consciousness, multiple organ dysfunction)
  • Pregnancy (either clinically confirmed or by urine dipstick for human chorionic gonadotrophin hormone)
  • Breastfeeding women
  • Localising features suggesting an alternative/additional diagnosis, e.g. pneumonia, sepsis
  • Renal failure (baseline eGFR < 30ml/min)
  • History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders
  • History of allergic disease, allergic reactions or known hypersensitivity to any component of the study product (Mild non-medication allergies allowed)
  • Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the participant
  • Participation or planned participation in a study involving the administration of an investigational compound within the past one month.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Standard of care (arm A)

Patients, who are randomly allocated into arm A will receive the standard of care (no study drug)

Experimentell: Molnupiravir (arm B)

Patients, who are randomly allocated into arm B, will receive 800mg po bid of Molnupiravir for 5 days

This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients.

In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed.

Andra namn:
  • Molnupiravir STELLA 400mg
Experimentell: Monoclonal antibody (arm C)

Patients, who are randomly allocated into arm C, will receive a single dose of 6mg/Kg of the dengue monoclonal antibody via an intravenous line over 2 hours.

VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.

Andra namn:
  • Dengue monoklonal antikropp (dengue mAb/Dv Mab)
Experimentell: Remdesivir (arm D)

Patients, who are randomly allocated into arm D, will receive:

  • Adults or children ≥ 40Kg: 200mg loading dose on day 1, followed by 100mg once daily from day 2 to day 5.
  • Children < 40Kg: 5mg/Kg loading dose on day 1, followed by 2.5mg/Kg once daily from day 2 to day 5.

Remdesivir (GS-443902) is a nucleoside analogue - RNA dependent RNA polymerase inhibitor.

Andra namn:
  • VEKLURY™ for IV Infusion 100 mg

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Viral clearance rate
Tidsram: From randomization until day 5 of study

Rate of viral clearance estimated under a hierarchical log-linear model fit to the serial viral load measurements over 5 days after enrolment. The viremia kinetics will be measured using the qRT-PCR assay, which will be performed on samples taken twice a day from day 1 to day 3 of study and then once a day on days 4 and 5 of study (total 9 samples per patient).

From randomization until day 5 of study
Number of AEs (grade 3, 4 and 5)
Tidsram: Until day 30 post-enrolment

All patients will be followed up daily until discharge and then at around days 30 after randomization to collect information on clinical progress of dengue illness and any adverse events occurring during the study course. All AEs and SAEs will be recorded.

Until day 30 post-enrolment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Area under the viremia curve
Tidsram: From randomisation until day 5 of study

Area under the curve (AUC) of the serial viremia measurements during the first 5 days of study

From randomisation until day 5 of study
Viral log reduction
Tidsram: up to 48 hours of study

Reduction of viremia at the 24 and 48 hours compared to baseline

up to 48 hours of study
NS1 clearance time
Tidsram: up to day 5

Time to NS1 clearance as estimated under a non-linear model

up to day 5
Number of patients progress to severe dengue (WHO 2009 criteria)
Tidsram: From enrolment until discharge, assessed up to 30 days

All patients will be followed up daily until discharge to collect information about the clinical progress of dengue

From enrolment until discharge, assessed up to 30 days
Number of patients requiring for ICU admission
Tidsram: From enrolment until discharge, assessed up to 30 days

All patients will be followed up daily until discharge to collect information about the clinical progress of dengue

From enrolment until discharge, assessed up to 30 days
Fever clearance time
Tidsram: From enrolment until discharge, assessed up to 30 days

Time elapsed from enrolment to the afebrile time-point (defined as body temperature <37.5 °C for at least 48 hours)

From enrolment until discharge, assessed up to 30 days
Platelet nadir
Tidsram: Until day 30 post-enrolment

The lowest platelet count recorded during admission

Until day 30 post-enrolment
Maximum AST/ALT
Tidsram: Until day 30 post-enrolment

The highest values of AST/ALT measured

Until day 30 post-enrolment
Change in haematocrit
Tidsram: Until day 30 post-enrolment

Change in haematocrit during the hospitalisation

Until day 30 post-enrolment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Sophie Yacoub, MD., PhD., University of Oxford, UK

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 april 2026

Primärt slutförande (Beräknad)

31 december 2029

Avslutad studie (Beräknad)

31 december 2030

Studieregistreringsdatum

Först inskickad

6 augusti 2024

Först inskickad som uppfyllde QC-kriterierna

11 augusti 2024

Första postat (Faktisk)

13 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 september 2026

Senast verifierad

1 april 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

The database may be shared with researchers not directly involved in this study but only after the main paper has been published and in accordance with OUCRU guidelines on data sharing. The database will only be shared if future publications are not compromised. No identifiable information will be shared with any other person/organisation than that authorised in the protocol.

Tidsram för IPD-delning

starting 6 months after publications of study findings

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera